Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Biochemistry of Coagulation Ahmad Shihada Silmi Msc, FIBMS Staff Specialist in Hematology Medical Technology Department Islamic University of Gaza 2012 The Protein C Anticoagulant Pathway Blood Flow Protein C Thrombin Thrombin APC Thrombomodulin Thrombus Thrombus at site of injury Anticoagulation downstream 12 The Protein C Anticoagulant Pathway Blood Flow Vai Factor V Leiden VIIIai VIIIa Va APC PS APC PS Thrombus 13 Proposed Mechanism of AT III-Heparin System Lysine sites AT III Serine site Thrombin Antithrombin III H Th Arginine site Heparin H AT III Th 15 Fibrinolytic Pathway Fibrinolysis is initiated when fibrin is formed and eventually dissolves the clot. 47 Fibrinolytic Pathway PAI-1 Plasminogen Tissue Plasminogen Activator (t-PA) Urokinase (uPA) Plasmin Inhibitor Exogenous: streptokinase XL-Fibrin, fibrinogen Plasmin XL- fibrin degradation products (FDP) 48 Degradation of Fibrin/Fibrinogen Fibrinogen or Fibrin Plasmin Fragment X Small Peptides Plasmin Fragment Y Fragment D Small Peptides Plasmin Fragment E Fragment D Small Peptides 49 Approach to evaluate Fibrinolysis D-Dimer, a measure of fibrin degradation products, is the final product formed during the fibrinolysis process by plasmin 50 Approach to evaluate Fibrinolysis cont, – Elevated levels of D-Dimer are indicative of on-going fibrinolysis • Found high in : • (DVT) • (PE) • (DIC) • D-Dimer levels also rise during the normal pregnancy and very high levels are associated with complications. 51 Bleeding Disorders 52 Clinical Features of Bleeding Disorders Platelet disorders Site of bleeding Petechiae Ecchymoses (“bruises”) Hemarthrosis / muscle bleeding Bleeding after cuts & scratches Bleeding after surgery or trauma Coagulation factor disorders Skin Mucous membranes (epistaxis, gum, vaginal, GI tract) Yes Small, superficial Extremely rare Yes Immediate, usually mild Deep in soft tissues (joints, muscles) No Large, deep Common No Delayed (1-2 days), often severe 53 Hematologic disorders causing bleeding – Coagulation factor disorders –Platelet disorders 54 Coagulation factor disorders Inherited bleeding disorders – Hemophilia A and B – Von Willebrands disease – Other factor deficiencies Acquired bleeding disorders – Liver disease – Vitamin K deficiency/warfarin overdose – DIC 55 Hemophilia A and B Coagulation factor deficiency Inheritance Incidence Severity Complications Hemophilia A Hemophilia B Factor VIII Factor IX X-linked recessive X-linked recessive 1/10,000 males 1/50,000 males Related to factor level <1% - Severe - spontaneous bleeding 1-5% - Moderate - bleeding with mild injury 5-25% - Mild - bleeding with surgery or trauma Soft tissue bleeding 56 Hemophilia Clinical manifestations (hemophilia A & B are indistinguishable) Hemarthrosis (most common) Fixed joints Soft tissue hematomas (e.g., muscle) Muscle atrophy Shortened tendons Other sites of bleeding Urinary tract CNS, neck (may be life-threatening) Prolonged bleeding after surgery or dental extractions 57 Hemarthrosis (acute) 58 von Willebrand Disease: Clinical Features von – – – – – Willebrand factor Synthesis in endothelium and megakaryocytes Forms large multimer Carrier of factor VIII Anchors platelets to subendothelium Bridge between platelets Inheritance Incidence Clinical - autosomal dominant - 1/10,000 features - mucocutaneous bleeding 59 Laboratory evaluation of von Willebrand disease Classification – Type 1 Partial quantitative deficiency – Type 2 Qualitative deficiency – Type 3 Total quantitative deficiency Diagnostic tests: Assay 1 vonWillebrand type 2 3 ___________________________________________________ vWF antigen vWF activity Multimer analysis Normal Normal Normal Absent 60 Vitamin K deficiency Source of vitamin K Green vegetables Synthesized by intestinal flora Required for synthesis Factors II, VII, IX ,X,Protein C and S Causes of deficiency Malnutrition Biliary obstruction Malabsorption Antibiotic therapy Treatment Vitamin K Fresh frozen plasma 61 Common clinical conditions associated with Disseminated Intravascular Coagulation • Activation of both coagulation and fibrinolysis Triggered by • Sepsis • Trauma – Head injury – Fat embolism • Malignancy • Obstetrical complications – Amniotic fluid embolism – Abruptio placentae • Vascular disorders • Reaction to toxin (e.g. snake venom, drugs) • Immunologic disorders – Severe allergic reaction – Transplant rejection 62 Disseminated Intravascular Coagulation (DIC) Mechanism Systemic activation of coagulation Intravascular deposition of fibrin Thrombosis of small and midsize vessels with organ failure Depletion of platelets and coagulation factors Bleeding 63 Pathogenesis of DIC Release of thromboplastic material into circulation Coagulation Fibrinolysis Fibrinogen Plasmin Thrombin Fibrin Monomers Fibrin Clot (intravascular) Consumption of coagulation factors; presence of FDPs aPTT PT TT Fibrinogen Presence of plasmin FDP Fibrin(ogen) Degradation Products Intravascular clot Platelets Schistocytes Plasmin 64 Classification of platelet disorders • Quantitative disorders – Abnormal distribution – Dilution effect – Decreased production – Increased destruction • Qualitative disorders – Inherited disorders (rare) – Acquired disorders • Medications • Chronic renal failure • Cardiopulmonary bypass 65 Laboratory Evaluation of Bleeding Overview CBC and smear Platelet count RBC and platelet morphology Thrombocytopenia TTP, DIC, etc. Coagulation Prothrombin time Partial thromboplastin time Coagulation factor assays 50:50 mix Fibrinogen assay Thrombin time fibrinogen defects FDPs or D-dimer Extrinsic/common pathways Intrinsic/common pathways Specific factor deficiencies Inhibitors (e.g., antibodies) Decreased fibrinogen Qualitative/quantitative von Willebrand factor Bleeding time Platelet function analyzer (PFA) Platelet function tests vWD In vivo test (non-specific) Qualitative platelet disorders and vWD Qualitative platelet disorders Platelet function Fibrinolysis (DIC) 66 Laboratory Evaluation of the Coagulation Pathways Partial thromboplastin time (PTT) Prothrombin time (PT) Surface activating agent (Ellagic acid, kaolin) Phospholipid Calcium Thromboplastin Tissue factor Phospholipid Calcium Intrinsic pathway Extrinsic pathway Thrombin time Common pathway Thrombin Fibrin clot 67 Pre-analytic errors Problems with blue-top tube – Hct ≥55 or ≤15 – Lipemia, hyperbilirubinemia, hemolysis – Partial fill tubes – Vacuum leak and citrate evaporation Problems with phlebotomy – – – – – Heparin contamination Wrong label Slow fill Underfill Vigorous shaking Biological effects Laboratory errors – Delay in testing – Prolonged incubation at 37°C – Freeze/thaw deterioration 68 Initial Evaluation of a Bleeding Patient - 1 Normal PT Normal PTT Urea solubility Abnormal Factor XIII deficiency Normal Consider evaluating for: Mild factor deficiency Abnormal fibrinolysis (a2 anti-plasmin def) Elevated FDPs Monoclonal gammopathy Platelet disorder Vascular disorder 69 Initial Evaluation of a Bleeding Patient - 2 Normal PT Abnormal PTT Repeat with 50:50 mix 50:50 mix is abnormal Test for inhibitor activity: Specific factors: VIII,IX, XI Non-specific (anti-phospholipid Ab) 50:50 mix is normal Test for factor deficiency: Isolated deficiency in intrinsic pathway (factors VIII, IX, XI) Multiple factor deficiencies (rare) 70 Initial Evaluation of a Bleeding Patient - 3 Abnormal PT Normal PTT Repeat with 50:50 mix 50:50 mix is abnormal Test for inhibitor activity: Specific: Factor VII (rare) Non-specific: Anti-phospholipid (rare) 50:50 mix is normal Test for factor deficiency: Isolated deficiency of factor VII (rare) Multiple factor deficiencies (common) (Liver disease, vitamin K deficiency, warfarin, DIC) 71 Initial Evaluation of a Bleeding Patient - 4 Abnormal PT Abnormal PTT Repeat with 50:50 mix 50:50 mix is abnormal Test for inhibitor activity: Specific : Factors V, X, Prothrombin, fibrinogen (rare) Non-specific: anti-phospholipid (common) 50:50 mix is normal Test for factor deficiency: Isolated deficiency in common pathway: Factors V, X, Prothrombin, Fibrinogen Multiple factor deficiencies (common) (Liver disease, vitamin K deficiency, warfarin, DIC) 72 Coagulation factor deficiencies Summary Sex-linked recessive Factors VIII and IX deficiencies cause bleeding Prolonged PTT; PT normal Autosomal recessive (rare) Factors II, V, VII, X, XI, fibrinogen deficiencies cause bleeding Prolonged PT and/or PTT Factor XIII deficiency is associated with bleeding and impaired wound healing PT/ PTT normal; clot solubility abnormal Factor XII, prekallikrein, HMWK deficiencies do not cause bleeding 73 Thrombin Time Bypasses factors II-XII Measures rate of fibrinogen conversion to fibrin Procedure: – Add thrombin with patient plasma – Measure time to clot Variables: – Source and quantity of thrombin 74 Causes of prolonged Thrombin Time Heparin Hypofibrinogenemia Dysfibrinogenemia Elevated FDPs or paraprotein Thrombin inhibitors (Hirudin) Thrombin antibodies 75 Approach to the thrombocytopenic patient History – Is the patient bleeding? – Are there symptoms of a secondary illness? (neoplasm, infection, autoimmune disease) – Is there a history of medications, alcohol use, or recent transfusion? – Are there risk factors for HIV infection? – Is there a family history of thrombocytopenia? – Do the sites of bleeding suggest a platelet defect? Assess the number and function of platelets – CBC with peripheral smear – Bleeding time or platelet aggregation study 76 77 Bleeding time and bleeding 5-10% of patients have a prolonged bleeding time Most of the prolonged bleeding times are due to aspirin or drug ingestion Prolonged bleeding time does not predict excess surgical blood loss Not recommended for routine testing in preoperative patients 78 Conclusion Special Coagulation is a specialized, complex and dynamic field! 79